Daniel Bode currently serves as an Associate at Angelini Ventures an has joined the team in October 2025. Prior to Angelini, Daniel has been a Senior Analyst at Forbion, where he was part of the Munich office since October 2023. During that time, Daniel has held 2 board observer seats and led the diligence on multiple deals, including Citryll.

Before transitioning into Biotech VC, Daniel has been Senior Business Development Associate and Program Lead at STRM.BIO, working on non-viral delivery to the bone marrow.

Daniel competed his PhD at the University of Cambridge in 2021 with a focus on Stem Cell Biology and Hematology. He is also proud to have contributed as COO to the organization of the 2018 GapSummit, the world’s first intergenerational biotech leadership forum.